[02 August 2021] The IBTA’s monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.
You can also read the IBTA e-News August 2021 edition in full online here.
Some of the highlights from this month’s round-up:
- We are delighted to announce that this year’s Brain Tumour magazine has now been published online and in print. The print magazine will shortly be distributed for free to recipients in 112 countries. If you would like to receive a copy of the 2021 IBTA magazine and are not on our mailing list, please fill in a subscription form here.
- The European Association of Neuro-Oncology (EANO) and the European Society for Medical Oncology (ESMO) have jointly published new guidelines for diagnosis, treatment and follow-up of patients with brain metastasis that have spread from solid tumours (excluding those which have spread from lymphoma, leukaemia, and elsewhere in the brain).
- The IBTA is hosting “Brilliance: A Virtual Exhibition of Creative Works from the Global Brain Tumour Community”. The art exhibition will be launched for viewing on the IBTA website (www.theibta.org) in conjunction with this year’s International Brain Tumour Awareness Week, running from Saturday, October 30 to Saturday, November 6, 2021.
- A collaborative study published in CA: A Cancer Journal for Clinicians has found that rates of malignant brain and other central nervous system (CNS) tumours have fallen by 0.8% year-on-year from 2008 to 2017 in the United States across all ages combined. The decline was driven by trends in adults. However, rates in children and adolescents have increased by 0.5% to 0.7% annually over the same period.
- TResearchers have used 3D-printing technology to create small, three-dimensional representations of individual patients’ glioblastoma tumours in the lab complete with a blood supply, according to a study published in the journal Science Advances.
- A phase 2 clinical trial involving 15 UK hospitals testing a cannabis-based mouth spray (nabiximols, brand name Sativex) in recurrent glioblastoma is planned to launch in 2022. Funds for the trial are currently being raised and it is hoped that 232 patients across the UK will be recruited into the study.
- A team of researchers has developed software that can reliably distinguish and classify brain tumours from a single 3D MRI scan, according to a study published in Radiology: Artificial Intelligence. Also published recently, a study in Scientific Reports highlights another machine-learning algorithm that can determine with 91–92% accuracy whether a brain tumour is a glioblastoma or a primary central nervous system lymphoma (PCNSL) on MRI.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.
